A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Public ClinicalTrials.gov record NCT03858634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus
Study identification
- NCT ID
- NCT03858634
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Interventions
- KPL-716 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2019
- Primary completion
- Mar 31, 2020
- Completion
- Jun 7, 2020
- Last update posted
- Mar 17, 2025
2019 – 2020
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 106 | Anniston | Alabama | 36207 | — |
| Site 110 | Phoenix | Arizona | 85032 | — |
| Site 114 | Hot Springs | Arkansas | 71913 | — |
| Site 103 | Los Angeles | California | 90045 | — |
| Site 113 | Sweetwater | Florida | 33172 | — |
| Site 105 | Normal | Illinois | 61761 | — |
| Site 112 | Plainfield | Indiana | 46168 | — |
| Site 119 | New Orleans | Louisiana | 70115 | — |
| Site 109 | Fort Gratiot | Michigan | 48059 | — |
| Site 123 | New York | New York | 10012 | — |
| Site 115 | Johnston | Rhode Island | 02919 | — |
| Site 104 | Pflugerville | Texas | 78660 | — |
| Site 101 | San Antonio | Texas | 78213 | — |
| Site 122 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03858634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03858634 live on ClinicalTrials.gov.